Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
8-K
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
12 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
PRE 14A
Preliminary proxy
1 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
6 Mar 24
8-K
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
27 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Other Events
31 Jan 24
8-K
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
4 Jan 24
8-K
Other Events
6 Dec 23
S-8
Registration of securities for employees
30 Nov 23
8-K
Other Events
14 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Adaptimmune Reports Third Quarter Financial Results and Business Update
8 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
8-K
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
31 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Aug 23
8-K/A
Financial Statements and Exhibits
10 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Adaptimmune Reports Second Quarter Financial Results and Business Update
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
8-K
Departure of Directors or Certain Officers
29 Jun 23
8-K
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
1 Jun 23
425
Business combination disclosure
30 May 23
8-K
Submission of Matters to a Vote of Security Holders
30 May 23
425
Business combination disclosure
22 May 23
8-K
Other Events
22 May 23
8-K
Submission of Matters to a Vote of Security Holders
16 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Adaptimmune Reports First Quarter Financial Results and Business Update
12 May 23
EFFECT
Notice of effectiveness
21 Apr 23
424B3
Prospectus supplement
20 Apr 23
CORRESP
Correspondence with SEC
18 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
8-K
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
11 Apr 23
UPLOAD
Letter from SEC
6 Apr 23
S-4
Registration of securities issued in business combination transactions
5 Apr 23
Latest ownership filings
SC 13D/A
New Enterprise Associates 14, L.P.
2 Apr 24
3
Initial statement of insider ownership
26 Mar 24
SC 13G/A
EcoR1 Capital, LLC
26 Mar 24
4
Cintia Piccina
18 Mar 24
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
EcoR1 Capital, LLC
30 Jan 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Adrian Rawcliffe
17 Jan 24
4
Elliot Norry
17 Jan 24
4
John Lunger
17 Jan 24
4
William C Bertrand JR
17 Jan 24
4
Ali Behbahani
17 Jan 24
4
William C Bertrand JR
17 Jan 24
4
Kristen Hege
17 Jan 24
4
John Lunger
17 Jan 24
4
Joanna Elizabeth Brewer
17 Jan 24
4
HELEN KATRINA TAYTON-MARTIN
17 Jan 24
4
Gavin Wood
17 Jan 24
4
Elliot Norry
17 Jan 24
4
Adrian Rawcliffe
17 Jan 24
4
Elliot Norry
12 Jan 24
4
William C Bertrand JR
12 Jan 24
4
Adrian Rawcliffe
12 Jan 24
4
John Lunger
12 Jan 24
SC 13G
Long Focus Capital Management, LLC
8 Nov 23
3
Kristen Hege
1 Nov 23
4
Adrian Rawcliffe
1 Sep 23
4
John Lunger
1 Aug 23
4
Garry E Menzel
10 Jul 23
SC 13G/A
Matrix Capital Management Company, LP
10 Jul 23
4
Priti Hegde
5 Jul 23
4
Andrew R Allen
5 Jul 23
4
Garry E Menzel
5 Jul 23
4
Ali Behbahani
3 Jul 23
4
Priti Hegde
3 Jul 23
4
John Furey
3 Jul 23
4
Garry E Menzel
3 Jul 23
4
Charles Elliott Sigal
3 Jul 23
4
Lawrence M Alleva
3 Jul 23